We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$73.7B
$28.3M 0.99%
135,712
+64,471
+90% +$12.6M
NBIX icon
27
Neurocrine Biosciences
NBIX
$16.8B
$28.2M 0.99%
294,234
+231,031
+366% +$22.3M
RMD icon
28
ResMed
RMD
$30.6B
$28.1M 0.99%
132,344
+35,275
+36% +$7.03M
DXCM icon
29
DexCom
DXCM
$31.5B
$27.6M 0.97%
298,572
+224,396
+303% +$20M
WAT icon
30
Waters Corp
WAT
$37B
$27.1M 0.95%
109,510
– –
PFE icon
31
Pfizer
PFE
$143B
$26M 0.91%
705,259
-1,082,080
-61% -$39.7M
MRNA icon
32
Moderna
MRNA
$21.8B
$25.9M 0.91%
248,192
-212,167
-46% -$21.5M
EXEL icon
33
Exelixis
EXEL
$13.3B
$25.2M 0.89%
1,256,520
+161,403
+15% +$3.38M
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$11.6B
$24.4M 0.86%
278,330
-47,492
-15% -$3.77M
EW icon
35
Edwards Lifesciences
EW
$49.6B
$24.2M 0.85%
264,955
-26,200
-9% -$2.17M
STE icon
36
Steris
STE
$22.3B
$24M 0.84%
126,779
– –
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$27.5B
$22.7M 0.8%
174,894
– –
MCK icon
38
McKesson
MCK
$100B
$22.7M 0.8%
130,448
+22,911
+21% +$3.82M
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
$22.1M 0.78%
175,838
+96,312
+121% +$10.8M
ARNA
40
DELISTED
Arena Pharmaceuticals Inc
ARNA
$19.4M 0.68%
252,971
+92,334
+57% +$6.92M
XRAY icon
41
Dentsply Sirona
XRAY
$2.68B
$19.2M 0.67%
365,927
-42,546
-10% -$2.1M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.4M 0.65%
83,784
+5,000
+6% +$1.08M
ALLK
43
DELISTED
Allakos
ALLK
$18.3M 0.64%
130,937
+66,540
+103% +$6.92M
ARGX icon
44
argenx
ARGX
$53.4B
$18.1M 0.64%
61,687
– –
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$4.43B
$17.7M 0.62%
331,789
+81,046
+32% +$4.02M
ISRG icon
46
Intuitive Surgical
ISRG
$127B
$17.4M 0.61%
63,888
-11,319
-15% -$2.81M
IDXX icon
47
Idexx Laboratories
IDXX
$44.1B
$17.4M 0.61%
34,814
– –
AZN icon
48
AstraZeneca
AZN
$263B
$17.2M 0.6%
172,167
– –
ADPT icon
49
Adaptive Biotechnologies
ADPT
$3.59B
$16.9M 0.59%
286,013
+261,298
+1,057% +$13.5M
TECH icon
50
Bio-Techne
TECH
$11.2B
$16.4M 0.58%
206,840
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.